

Oncotarget, Supplementary Materials 2017

Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a nonendemic area


SUPPLEMENTARY FIGURES



Supplementary Figure 1: Kaplan-Meier survival curves showing the probability of DFS in locally advanced EBER positive NPC patients, post-hoc analysis. DFS= Disease Free Survival. EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable ($0 \le \text{EBV DNA} \le 10^2$ copies/mL); Q, Positive and quantifiable ($10^2 \le \text{EBV DNA} \le 15 \times 10^2$ copies/mL); Q+, Strongly positive and quantifiable (EBV DNA > 15 x 10² copies/mL).



Supplementary Figure 2: Kaplan-Meier survival curves showing the probability of OS in locally advanced EBER positive NPC patients, post-hoc analysis. OS= Overall Survival. EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable ($0 \le \text{EBV DNA} \le 10^2$ copies/mL); Q, Positive and quantifiable ($10^2 \le \text{EBV DNA} \le 15 \times 10^2$ copies/mL); Q+, Strongly positive and quantifiable (EBV DNA > 15×10^2 copies/mL).



Supplementary Figure 3: Results of Tukey HSD test, post-hoc analysis. EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable ($0 \le EBV DNA \le 10^2$ copies/mL); Q, Positive and quantifiable ($10^2 \le EBV DNA \le 15 x 10^2$ copies/mL); Q+, Strongly positive and quantifiable (EBV DNA > $15 x 10^2$ copies/mL). The upper panel shows the results of the Tukey's HSD test: *P* values corresponding to the difference between group pairs are displayed. Highlighted values are statistically significant (*P*<0.05). The lower panel shows the median values of the three groups and their confidence intervals.